Pharming Group N.V. ADS Company Profile
NASDAQ: PHARHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Pharming Group N.V. at a glance
Pharming Group N.V. ADS (NASDAQ: PHAR) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Leiden, Netherlands. Pharming Group N.V. is led by Mr. Kenneth Lynard EMBA, M.Sc. and employs about 407 people. At a market capitalization of $816.8 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001828316, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Pharming Group N.V. do?
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Business description based on the company's public filings.
Company information
- Legal name
- Pharming Group N.V. ADS
- Ticker
- NASDAQ: PHAR
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Kenneth Lynard EMBA, M.Sc.
- Employees
- 407
- Headquarters
- Darwinweg 24, Leiden, Netherlands
- Phone
- 31 71 524 7400
- Website
- pharming.com
- Market cap
- $816.78M
- SEC CIK
- 0001828316
Companies similar to Pharming Group N.V.
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRVSCorvus Pharmaceuticals Inc. | 9.67 | -3.40% | $815.69M | vs PHAR |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs PHAR |
| SNDXSyndax Pharmaceuticals Inc. | 8.72 | -4.49% | $785.05M | vs PHAR |
| IRWDIronwood Pharmaceuticals Inc. Class A | 4.70 | -0.21% | $778.09M | vs PHAR |
| MTRIMentari Therapeutics Inc. | 14.70 | -3.57% | $856.94M | vs PHAR |
| LTGOLatigo Biotherapeutics Inc. | 13.00 | -1.81% | $861.89M | vs PHAR |
| COLLCollegium Pharmaceutical Inc. | 24.72 | -1.94% | $768.18M | vs PHAR |
| ORICOric Pharmaceuticals Inc. | 7.36 | -4.42% | $764.94M | vs PHAR |